Frontlight ResearchEarly access
CompletedNo phase
Post COVID-19 Interstitial Lung Disease: A Study of Genetic and Environmental Interactions
Key facts
- Who runs it
- Imperial College London
- Where
- United Kingdom4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 40 people enrolled
- Started
- 1 Jul 2021
- Ended
- 1 Apr 2024
- Type of study
- Observational
- Record updated
- 18 April 2024
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Evidence of SARS-CoV-2 PCR/Seropositive
- Presence of interstitial lung disease on CT
- Participant is willing and able to give informed consent for participation in the study
- Aged 18 years or above
Who cannot take part
- Confirmed ILD diagnosis prior to March 2020
- Use of steroids at baseline visit
- Patients with co-morbid disease that in the opinion of the investigators gives them an expected life expectancy of less than one year will be excluded from the study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to understand why some people who have had COVID-19 develop scarring of the lungs and why some people recover more quickly than others.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- POST COvid-19 Interstitial Lung DiseasE (POSTCODE) A Study of Genetic and Environmental Interactions: an Observational Cohort Study.
- Record updated
- 18 April 2024